Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
Open Access
- 11 October 2006
- journal article
- research article
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 4 (1) , 1-80
- https://doi.org/10.1186/1477-7525-4-80
Abstract
Patient-reported measures can be used to examine whether drug differences other than clinical efficacy have an impact on outcomes that may be important to patients. Although exenatide and insulin glargine appear to have similar efficacy for treatment of type 2 diabetes, there are several differences between the two treatments that could influence outcomes from the patient's perspective. The purpose of the current study was to examine whether the two drugs were comparable as assessed by patient-reported outcomes using data from a clinical trial in which these injectable medications were added to pre-existing oral treatment regimens.This publication has 68 references indexed in Scilit:
- Development and Validation of the Gastroesophageal Reflux Disease Treatment Satisfaction QuestionnaireDigestive Diseases and Sciences, 2005
- ExenatideDrugs, 2005
- A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes MellitusDrugs, 2005
- Patient assessment of treatment satisfaction: methods and practical issuesGut, 2004
- Insulin glargine: long-acting basal insulin analog for improved metabolic controlCurrent Medical Research and Opinion, 2004
- Patient perceptions of diabetes and diabetes therapy: assessing quality of lifeDiabetes/Metabolism Research and Reviews, 2002
- Methods to Explain the Clinical Significance of Health Status MeasuresMayo Clinic Proceedings, 2002
- A Comparative Review of Generic Quality-of-Life InstrumentsPharmacoEconomics, 2000
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Measurement of health statusControlled Clinical Trials, 1989